We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The federal, provincial and territorial governments and two pharmaceutical companies will embark on a three-year study to investigate the efficacy of two contentious and expensive drugs used in the treatment of Fabry disease.
Israeli drugmaker Teva Pharmaceutical has announced that the U.S. FDA has granted tentative approval for its abbreviated new drug application (ANDA) for losartan potassium and hydrochlorothiazide tablets.
New York-based Barr Laboratories will pay $22.5 million to Sandoz to settle a lawsuit that alleged Barr unlawfully blocked access to the raw material source for warfarin sodium, Barr said June 12, the day the trial was to start.
Spanish pharmaceutical company Almirall, and Meda, based in Sweden, have entered into an agreement regarding Meda's inhalation products division the business sector that develops the Novolizer, a multidose dry-powder inhaler for administration of products to treat respiratory conditions.
Indian drugmaker Zydus Cadila has received tentative approval from the U.S. FDA to market pravastatin sodium tablets in the U.S. market, the company reported.
The Indian pharmaceutical industry seems set to emerge from the confies of the generics market in which it has largely positioned itself and could soon become a major player on the global scene.
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced an agreement with Green Cross Corporation, South Korea for the development and commercialization in Korea of peramivir, BioCryst's potent influenza neuraminidase inhibitor.
Sigma-Aldrich, a $1.7 billion Life Science company, and Oxford BioMedica, a leading gene therapy company, have announced today that they have filed a lawsuit against Open Biosystems, Inc. for infringement of key patents that cover key lentiviral-based systems for delivery of foreign DNA to a broad array of mammalian cells.